Fatal pneumococcal sepsis in a patient with hidradenitis suppurativa treated with infliximab;Sepsis neumocócica fatal en un paciente con hidrosadenitis supurativa en tratamiento con infliximab

Medicina Clinica

Volumn 131, Issue 20, 2008, Pages 799-

  Benítez Macías, Juan Francisco ^a   García Gil, Daniel ^a   Brun Romero, Francisco Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PIPERACILLIN PLUS TAZOBACTAM; POLYSACCHARIDE; VACCINE; VANCOMYCIN;

ADULT; CASE REPORT; CONFUSION; DIARRHEA; DISORIENTATION; FEVER; HUMAN; HYPOTENSION; LETTER; MALE; MULTIPLE ORGAN FAILURE; RESTLESSNESS; SEPSIS; SHOCK; SUPPURATIVE HIDRADENITIS; TACHYCARDIA; TACHYPNEA; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; FATAL OUTCOME; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63549116201     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(08)75512-X     Document Type: Letter

References (10)

1. Fernández-Vozmediano J.M., and Armario-Hita J.C. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 215 (2007) 41-44
2. García-Lechuz Moya J.M. I Complicaciones infecciosas asociadas al uso de fármacos antagonistas del factor de necrosis tumoral. Revisión de conjunto 551. Enferm Infecc Microbiol Clin 23 (2005) 551-559
3. Maini R., Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) vs placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
4. Salliot C., Gossec L., Ruyssen-Witrand A., Luc M., Duclos M., Guignard S., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 46 (2007) 327-334
5. Kroesen S., Widmer A.F., Tyndall A., and Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 42 (2003) 617-621
6. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
7. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48 (2003) 3013-3022
8. Takashima K., Tateda K., Matsumoto T., Iizawa Y., Nakao M., and Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 65 (1997) 257-260
9. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med. 2007;147:725-9.
10. Wright S.A., and Taggart A.J. Pneumococcal vaccination for RA patients on TNF-alpha antagonists. Rheumatology 43 (2004) 523